STOCK TITAN

BillionToOne (NASDAQ: BLLN) updates outlook, sets 2026 financial guidance

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BillionToOne, Inc. filed a current report stating that it issued a press release on January 12, 2026, reiterating its guidance for the full year ended December 31, 2025 and initiating guidance for full year 2026. This means the company confirmed its prior outlook for 2025 while also providing its initial expectations for 2026.

The company also noted that the investor presentation used at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 will be posted on the Investor page of its website under the “Events & Presentations” section.

Positive

  • None.

Negative

  • None.
FALSE000207084900020708492026-01-122026-01-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
___________________________________
BillionToOne, Inc.
(Exact name of Registrant as specified in its charter)
___________________________________
Delaware
001-42934
81-1082020
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1035 O’Brien Drive
Menlo Park, CA 94025
(Address of principal executive offices including zip code)
Registrant’s telephone number, including area code: (650) 460-2551

(Former name or former address, if changed since last report)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Class A common stock, par value $0.00001 per share
BLLN
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, BillionToOne, Inc. (the “Company”) issued a press release reiterating its guidance for the full year ended December 31, 2025, and initiating its full year 2026 guidance. A copy of the Company’s press release is attached hereto as Exhibit 99.1.


Item 7.01 Regulation FD Disclosure

The Company will post the presentation that it will present at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 to the Investor page of the Company’s website (https://investors.billiontoone.com/), on the “Events & Presentations” page under “News and Events.”

The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits.

Exhibit
Description
99.1
Press Release of BillionToOne, Inc., dated January 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BillionToOne, Inc.
Date:
January 12, 2026
By:
/s/ Ross Taylor
Name:
Ross Taylor
Title:
Chief Financial Officer


FAQ

What did BillionToOne (BLLN) disclose in this 8-K filing?

The company disclosed that it issued a press release on January 12, 2026 reiterating its full-year 2025 guidance and initiating full-year 2026 guidance, and that it will post its 2026 J.P. Morgan Healthcare Conference presentation on the Investor page of its website.

What period does BillionToOne’s reiterated guidance cover?

BillionToOne reiterated its guidance for the full year ended December 31, 2025.

What new outlook did BillionToOne provide alongside reiterating 2025 guidance?

Alongside reiterating its full-year 2025 guidance, BillionToOne initiated its guidance for the full year 2026.

Where can investors find BillionToOne’s 2026 J.P. Morgan Healthcare Conference presentation?

Investors can find the presentation on the Investor page of BillionToOne’s website (https://investors.billiontoone.com/) under the “Events & Presentations” section in “News and Events.”

Is the BillionToOne press release in this 8-K treated as filed or furnished?

The information in this report, including Exhibit 99.1, is furnished and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into other filings, except as expressly set forth by specific reference.

Who signed this BillionToOne 8-K report?

The report was signed on behalf of BillionToOne, Inc. by Ross Taylor, the company’s Chief Financial Officer.
BillionToOne, Inc.

NASDAQ:BLLN

BLLN Rankings

BLLN Latest News

BLLN Latest SEC Filings

BLLN Stock Data

4.06B
5.60M